1. Home
  2. Companies
  3. NYR
  4. Material Events

Nyrada (ASX:NYR) — Material Events

ASX:NYR · 9 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 7 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
7
Nyrada secures AU$12 million to fund Xolatryp trial and expand biotech pipelineHigh
Nyrada launches A$14m capital raise to fund Phase IIa trial and expand TRPC drug pipeline
21 Sept 2026 ·Capital Raising Presentation ·88
Nyrada expands Xolatryp trial as FDA feedback clears path to 2027 INDHigh
Nyrada advances Xolatryp trials, secures FDA support and raises AU$12 million
19 Oct 2026 ·Quarterly Activities Report and Appendix 4C ·86
Nyrada Doses First Patient in Xolatryp Phase IIa Trial, Secures US Patent AllowanceMedium
Nyrada advances Xolatryp Phase IIa trial, secures US patent allowance, and reports strong cash position
27 July 2026 ·Quarterly Activities Report and Appendix 4C ·85
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.